This report was first published by Endpoints News. To see the original version, click here
Genmab has stopped enrolling patients for an early-stage trial of a cancer candidate it obtained in its $1.8 billion acquisition of US-China biotech ProfoundBio.
The Phase 1/2 study of GEN1286 was meant to enroll 260 patients with advanced solid tumors, but it has stopped at just 23, according to an update on ClinicalTrials.gov this month. The update also notes that the trial is “active, not recruiting.” Genmab confirmed to Endpoints News that the information is accurate, but declined to provide further comment.
您已阅读35%（606字），剩余65%（1103字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。